298 related articles for article (PubMed ID: 16799963)
1. Different anti-HCV profiles of statins and their potential for combination therapy with interferon.
Ikeda M; Abe K; Yamada M; Dansako H; Naka K; Kato N
Hepatology; 2006 Jul; 44(1):117-25. PubMed ID: 16799963
[TBL] [Abstract][Full Text] [Related]
2. Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients.
Milazzo L; Meroni L; Galazzi M; Cesari M; Caramma I; Marchetti G; Galli M; Antinori S
J Viral Hepat; 2009 Jul; 16(7):479-84. PubMed ID: 19215577
[TBL] [Abstract][Full Text] [Related]
3. Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon.
Ikeda M; Kato N
J Pharmacol Sci; 2007 Oct; 105(2):145-50. PubMed ID: 17928739
[TBL] [Abstract][Full Text] [Related]
4. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
[TBL] [Abstract][Full Text] [Related]
5. Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b.
Atsukawa M; Tsubota A; Kondo C; Itokawa N; Narahara Y; Nakatsuka K; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Kanazawa H; Sakamoto C
J Gastroenterol Hepatol; 2013 Jan; 28(1):51-6. PubMed ID: 22989264
[TBL] [Abstract][Full Text] [Related]
6. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development.
Delang L; Paeshuyse J; Vliegen I; Leyssen P; Obeid S; Durantel D; Zoulim F; Op de Beeck A; Neyts J
Hepatology; 2009 Jul; 50(1):6-16. PubMed ID: 19437494
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.
Okuse C; Rinaudo JA; Farrar K; Wells F; Korba BE
Antiviral Res; 2005 Jan; 65(1):23-34. PubMed ID: 15652968
[TBL] [Abstract][Full Text] [Related]
8. Anti-ulcer agent teprenone inhibits hepatitis C virus replication: potential treatment for hepatitis C.
Ikeda M; Kawai Y; Mori K; Yano M; Abe K; Nishimura G; Dansako H; Ariumi Y; Wakita T; Yamamoto K; Kato N
Liver Int; 2011 Jul; 31(6):871-80. PubMed ID: 21645219
[TBL] [Abstract][Full Text] [Related]
9. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
10. Antiviral action of interferon-alpha against hepatitis C virus replicon and its modulation by interferon-gamma and interleukin-8.
Jia Y; Wei L; Jiang D; Wang J; Cong X; Fei R
J Gastroenterol Hepatol; 2007 Aug; 22(8):1278-85. PubMed ID: 17565587
[TBL] [Abstract][Full Text] [Related]
11. Are statins a viable option for the treatment of infections with the hepatitis C virus?
Verpaalen B; Neyts J; Delang L
Antiviral Res; 2014 May; 105():92-9. PubMed ID: 24613180
[TBL] [Abstract][Full Text] [Related]
12. Fluvastatin inhibits hepatitis C replication in humans.
Bader T; Fazili J; Madhoun M; Aston C; Hughes D; Rizvi S; Seres K; Hasan M
Am J Gastroenterol; 2008 Jun; 103(6):1383-9. PubMed ID: 18410471
[TBL] [Abstract][Full Text] [Related]
13. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
[TBL] [Abstract][Full Text] [Related]
14. Oncostatin M synergistically inhibits HCV RNA replication in combination with interferon-alpha.
Ikeda M; Mori K; Ariumi Y; Dansako H; Kato N
FEBS Lett; 2009 May; 583(9):1434-8. PubMed ID: 19332062
[TBL] [Abstract][Full Text] [Related]
15. Role of statins in the treatment of chronic hepatitis C virus infection.
Abd-Eldaem AA; Azmy MK; Ahmad YK; Badr GA; Houssein MA; El-Dahshan T
J Egypt Soc Parasitol; 2012 Dec; 42(3):535-40. PubMed ID: 23469629
[TBL] [Abstract][Full Text] [Related]
16. Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-alpha against hepatitis C virus.
Liu WL; Su WC; Cheng CW; Hwang LH; Wang CC; Chen HL; Chen DS; Lai MY
J Infect Dis; 2007 Aug; 196(3):425-34. PubMed ID: 17597457
[TBL] [Abstract][Full Text] [Related]
17. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo.
Abe H; Imamura M; Hiraga N; Tsuge M; Mitsui F; Kawaoka T; Takahashi S; Ochi H; Maekawa T; Hayes CN; Tateno C; Yoshizato K; Murakami S; Yamashita N; Matsuhira T; Asai K; Chayama K
J Hepatol; 2011 Jul; 55(1):11-8. PubMed ID: 21145867
[TBL] [Abstract][Full Text] [Related]
18. Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response.
Landau DA; Saadoun D; Halfon P; Martinot-Peignoux M; Marcellin P; Fois E; Cacoub P
Arthritis Rheum; 2008 Feb; 58(2):604-11. PubMed ID: 18240235
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea as an inhibitor of hepatitis C virus RNA replication.
Nozaki A; Morimoto M; Kondo M; Oshima T; Numata K; Fujisawa S; Kaneko T; Miyajima E; Morita S; Mori K; Ikeda M; Kato N; Tanaka K
Arch Virol; 2010 Apr; 155(4):601-5. PubMed ID: 20204428
[TBL] [Abstract][Full Text] [Related]
20. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells.
Lin K; Kwong AD; Lin C
Antimicrob Agents Chemother; 2004 Dec; 48(12):4784-92. PubMed ID: 15561857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
